Core--Pathology/Genotyping
核心--病理学/基因分型
基本信息
- 批准号:7102939
- 负责人:
- 金额:$ 42.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The Southwest Oncology Group-led Prostate Cancer
Prevention Trial (PCPT) was the first large-scale chemoprevention trial for prostate cancer (PCa). This trial, which enrolled >18,800 men, tested the ability of the 5-alpha-reductase inhibitor finasteride to reduce the period-prevalence of biopsy-proven PCa over a period of 7 years. A byproduct of the PCPT was the establishment of large specimen banks of biopsy tissue, prostatectomy specimens, serum, plasma, and white blood cells obtained from the participants at the end of the study and at various interim time points during the study. The overall aim of this revised application for Core C is to establish a Pathology and Genotyping Core in support of the molecular "Biology of the PCPT" Program Project. This core will provide expertise and resources in the following areas: 1) Archival Repository Management and Distribution of the various specimen banks established from the PCPT; 2) Histopathology, including diagnostic interpretation, microtomy, microscopy, laser-capture microdissection (LCM), immunohistochemistry (IHC), and computer-assisted image analysis; and 3) Genotyping and hormone analysis, overseeing the isolation of DNA, genotyping of samples and hormone analysis to be carried out by specialized central facilities. This revised proposal addresses all of the comments from the review of the original proposal and adds new preliminary data regarding reliability and quantification of IHC, quantification of DNA extracted from serum, and extraction and amplification of DNA from paraffin-embedded tissue sections using LCM. Genotyping has also been streamlined to ensure sufficient DNA for the proposed studies and for future PCPT biology studies. Our intent is to provide the highest quality samples and pathological services to meet the needs of the research teams in the Program Project. It is our underlying hypothesis that the quality, reliability and
applicability of translational research in PCa can only be guaranteed through the use of high-quality biological specimens that are handled, processed and interpreted in a uniform manner and that can be linked to clinical information and outcome.
描述(由申请人提供):西南肿瘤组领导的前列腺癌
预防试验(PCPT)是第一个大规模的前列腺癌(PCa)化学预防试验。这项试验招募了超过18,800名男性,测试了5-α-还原酶抑制剂芬那鲁德在7年内降低活检证实的PCa周期患病率的能力。PCPT的一个副产品是在研究结束时和研究期间的各个中间时间点从参与者中获得的活检组织、子宫切除术标本、血清、血浆和白色血细胞的大型标本库的建立。核心C的修订申请的总体目标是建立病理学和基因分型核心,以支持分子“PCPT生物学”计划项目。该核心将在以下领域提供专门知识和资源:1)档案库管理和分发从PCPT建立的各种标本库; 2)组织学,包括诊断解释、切片术、显微镜、激光捕获显微切割(LCM)、免疫组织化学(IHC)和计算机辅助图像分析;基因分型和激素分析,监督由专门的中央设施进行的DNA分离、样本基因分型和激素分析。本修订提案解决了原始提案审查中的所有意见,并增加了有关IHC可靠性和定量、血清中提取的DNA定量以及使用LCM从石蜡包埋组织切片中提取和扩增DNA的新的初步数据。还对基因分型进行了简化,以确保为拟议的研究和未来的五氯苯酚生物学研究提供足够的DNA。我们的目的是提供最高质量的样本和病理服务,以满足项目研究团队的需求。我们的基本假设是,
转化研究在PCa中的适用性只能通过使用高质量的生物标本来保证,这些生物标本以统一的方式处理,加工和解释,并且可以与临床信息和结果联系起来。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SCOTT M LIPPMAN其他文献
SCOTT M LIPPMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SCOTT M LIPPMAN', 18)}}的其他基金
Biology of the Prostate Cancer Prevention Trial (PCPT)
前列腺癌预防试验 (PCPT) 的生物学
- 批准号:
6907173 - 财政年份:2005
- 资助金额:
$ 42.26万 - 项目类别:
Biology of the Prostate Cancer Prevention Trial (PCPT)
前列腺癌预防试验 (PCPT) 的生物学
- 批准号:
7418582 - 财政年份:2005
- 资助金额:
$ 42.26万 - 项目类别:
IGF-1Axis and Insulin Resistance in PCPT
PCPT 中的 IGF-1 轴和胰岛素抵抗
- 批准号:
7102930 - 财政年份:2005
- 资助金额:
$ 42.26万 - 项目类别:
Genotypic and Phenotypic Studies of Inflammation in PCPT
PCPT 炎症的基因型和表型研究
- 批准号:
7102931 - 财政年份:2005
- 资助金额:
$ 42.26万 - 项目类别:
Biology of the Prostate Cancer Prevention Trial (PCPT)
前列腺癌预防试验 (PCPT) 的生物学
- 批准号:
7059466 - 财政年份:2005
- 资助金额:
$ 42.26万 - 项目类别:
相似海外基金
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy
开发微流控 CRISPR-Cas9 功能基因筛选技术,用于癌症免疫治疗中靶点发现
- 批准号:
10549221 - 财政年份:2022
- 资助金额:
$ 42.26万 - 项目类别:
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy
开发微流控 CRISPR-Cas9 功能基因筛选技术,用于癌症免疫治疗中靶点发现
- 批准号:
10673007 - 财政年份:2022
- 资助金额:
$ 42.26万 - 项目类别:
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy
开发微流控 CRISPR-Cas9 功能基因筛选技术,用于癌症免疫治疗中靶点发现
- 批准号:
10188940 - 财政年份:2021
- 资助金额:
$ 42.26万 - 项目类别:
Genetic screening and therapies for nemaline myopathies
线状肌病的基因筛查和治疗
- 批准号:
9093821 - 财政年份:2014
- 资助金额:
$ 42.26万 - 项目类别:
Genetic screening and therapies for nemaline myopathies
线状肌病的基因筛查和治疗
- 批准号:
8631162 - 财政年份:2014
- 资助金额:
$ 42.26万 - 项目类别:
IGF::OT::IGF: SMOKESCREEN: GENETIC SCREENING TOOL FOR TOBACCO DEPENDENCE & TREAT
IGF::OT::IGF:SmokeScreen:烟草依赖性基因筛查工具
- 批准号:
8704651 - 财政年份:2013
- 资助金额:
$ 42.26万 - 项目类别:
IGF::OT::IGF: SMOKESCREEN: GENETIC SCREENING TOOL FOR TOBACCO DEPENDENCE & TREAT
IGF::OT::IGF:SmokeScreen:烟草依赖性基因筛查工具
- 批准号:
9061481 - 财政年份:2013
- 资助金额:
$ 42.26万 - 项目类别:
OTHER FUNCTIONS: SMOKESCREEN: GENETIC SCREENING TOOL FOR TOBACCO DEPENDENCE AND
其他功能:SmokeScreen:烟草依赖的基因筛查工具
- 批准号:
8507957 - 财政年份:2012
- 资助金额:
$ 42.26万 - 项目类别:
The Ethics of Fragile X Genetic Screening and Testing Across the Lifespan
整个生命周期中脆性 X 基因筛查和测试的伦理
- 批准号:
8235080 - 财政年份:2008
- 资助金额:
$ 42.26万 - 项目类别:
The Ethics of Fragile X Genetic Screening and Testing Across the Lifespan
整个生命周期中脆性 X 基因筛查和测试的伦理
- 批准号:
7628999 - 财政年份:2008
- 资助金额:
$ 42.26万 - 项目类别:














{{item.name}}会员




